Clinical Trial Update: Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients [Phase 1]

View source ↗

Summary

Phase 1 surface area study of Firategrast (SB683699) in multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Firategrast (SB683699) (Firategrast)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Sclerosis | Phase 1 | Status: COMPLETED